PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 5, 2026MoleculesOpen Access

A Novel Approach for the Synthesis of Peripherally Acting Dual Target Inhibitor of Cannabinoid-1 (CB1 Receptor) and Inducible Nitric Oxide Synthase (iNOS) (S-MRI-1867/Zevaquenabant)

View Full Paper
Ask AI
Bookmark
Share

Authors

MIMalliga R. Iyer

Discussion

Loading...

Member takes

Overview

This report describes a new synthesis route for a dual target inhibitor, highlighting implications for drug development.

Key Points

  • To develop a novel synthetic route for a peripherally acting dual target inhibitor of CB1R and iNOS.
  • Utilize a chiral thio-substituted leaving group from a Bunte-salt reaction approach.
  • Synthesize diastereomeric compounds that are further processed to enantiopure compounds.
  • Rapidly assemble a variety of chiral sulfonyl amino compounds.
  • Successful synthesis of a selective antagonist of CB1R and an inhibitor of iNOS.
  • Demonstrated efficiency in producing diastereomeric compounds.
  • Establishment of a method for assembling chiral sulfonyl amino compounds.

Cite This Study

Malliga R. Iyer (2026) studied this question.

synapsesocial.com/papers/6984345ff1d9ada3c1fb2732https://doi.org/10.3390/molecules31030515
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Synthesis and pharmacological characterization of UVI3502, a novel cannabinoid receptor 1 (CB1) antagonist/inverse agonist2024
  2. 2Quinazoline-2,4(1H,3H)-dione derivatives as new class of CB1 Agonists: A pharmacophore-based virtual screening workflow and Lead discovery2025
  3. 3Quinazoline-2,4(1H,3H)-dione derivatives as new class of CB1 Agonists: A pharmacophore-based virtual screening workflow and Lead discovery2025
  4. 4A Highly Potent, Orally Bioavailable Pyrazole-Derived Cannabinoid CB2 Receptor- Selective Full Agonist for <i>In Vivo</i> Studies2024 · 3 citations
  5. 5Pharmacological evaluation of new generation OXIZID synthetic cannabinoid receptor agonists2024 · 13 citations